SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

JNJ-303

Item No. 37345

CAS Registry No.:	878489-28-2
Formal Name:	2-(4-chlorophenoxy)-2-methyl-N-[5-[(methylsulfonyl)amino] tricyclo[3.3.1.13,7]dec-2-yl]-propanamide, stereoisomer
MF:	$C_{21}H_{29}ClN_2O_4S$
FW:	441.0
Purity:	≥98%
UV/Vis.:	λ_{max}: 225 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JNJ-303 is supplied as a solid. A stock solution may be made by dissolving the JNJ-303 in the solvent of choice, which should be purged with an inert gas. JNJ-303 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of JNJ-303 in these solvents is approximately 1 mg/ml.

Description

JNJ-303 is an inhibitor of voltage-gated potassium channel $K_V7.1$ (IC_{50} = 0.064 µM).[1] It is selective for inhibiting $K_V7.1$ currents (I_{Ks}) over I_{Na}, I_{Kr}, I_{to}, I_{K1}, and I_{CaL} (IC_{50}s =3.3, 12.6, 11.1, >100, and >10 µM, respectively). It selectively inhibits the heteromeric $K_V7.1$-KCNE1 complex (IC_{50} = 0.0784 µM) with no effect on homomeric $K_V7.1$, $K_V7.2$, or $K_V1.5$ in *Xenopus* oocytes at 1 µM.[2] JNJ-303 prolongs the QT interval and also induces pause-dependent torsade de pointes (TdP) in anesthetized dogs when used at doses of 0.63 and 1.25 mg/kg, respectively.[1]

References

1. Towart, R., Linders, J.T.M., Herman, A.N., *et al.* Blockade of the I_{KS} potassium channel: An overlooked cardiovascular liability in drug safety screening? *J. Pharmacol. Toxicol. Methods* **60(1)**, 1-10 (2009).
2. Wrobel, E., Rothenberg, I., Krisp, C., *et al.* KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting. *Nat. Commun.* **7**, 12795 (2016).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM